Use of alefacept and etanercept in 3 patients whose psoriasis failed to respond to etanercept - 09/08/11
Doi : 10.1016/j.jaad.2005.08.032
Correspondence to: James M. Krell, MD, Total Skin and Beauty Dermatology Center, 2100 16th Ave South, Ste 202, Ash Place, Birmingham, AL 35205.Birmingham, Alabama
Abstract |
This article reports on the combined use of alefacept and etanercept in 3 patients whose psoriasis failed to respond adequately to etanercept. All patients maintained improvement for at least 8 weeks after completing 12 weeks of alefacept. No adverse events or infections were reported, and CD4+ T-cell counts remained above normal limits.
Le texte complet de cet article est disponible en PDF.Plan
| Funding sources: Research support from Abbott Laboratories, Biogen Idec, Genentech, and Synta Pharmaceuticals. Conflicts of interest: Dr Krell is a consultant and speakers’ bureau participant for Amgen, Biogen Idec, and Genentech. Reprints not available from the author. |
© 2006
American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 54 - N° 6
P. 1099-1101 - juin 2006 Retour au numéro
Article précédent
- What’s new online?
- Etanercept therapy in two patients with psoriasis and concomitant hepatitis C
- Clara De Simone, Andrea Paradisi, Rodolfo Capizzi, Angelo Carbone, Massimo Siciliano, Pier Luigi Amerio
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?